ACE2 activation promotes antithrombotic activity

Molecular Medicine

Volumn 16, Issue 5-6, 2010, Pages 210-215

  Fraga Silva, Rodrigo A ^a   Sorg, Brian S ^a   Wankhede, Mamta ^a   deDeugd, Casey ^a   Jun, Joo Y ^a   Baker, Matthew B ^a   Li, Yan ^a   Castellano, Ronald K ^a   Katovich, Michael J ^a   Raizada, Mohan K ^a   Ferreira, Anderson J ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN CONVERTING ENZYME 2 ACTIVATOR; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE; ENZYME ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL OCCLUSION; CAVA VEIN; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; THROMBOCYTE ADHESION; THROMBOGENESIS; THROMBOSIS; WESTERN BLOTTING; WISTAR KYOTO RAT;

ANALYSIS OF VARIANCE; ANIMALS; MALE; MICE; MICE, NUDE; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED SHR; RATS, INBRED WKY; THROMBOSIS; XANTHONES;

EID: 77951955278     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2009.00160     Document Type: Article

References (28)

1. Willoughby S, Holmes A, Loscalzo J. (2002) Platelets and cardiovascular disease. Eur. J. Car-diovasc. Nurs. 1:273-88
2. Lip GY. (2003) Hypertension, platelets, and the endothelium: the "thrombotic paradox" of hypertension (or "Birmingham paradox") revisited. Hypertension. 41:199-200
3. Dzau VJ. (2001) Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular dis-ease: a unifying hypothesis. Hypertension. 37:1047-52
4. Donoghue M, et al. (2000) A novel angiotensin- converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87:E1-9
5. Ferreira AJ, Raizada MK. (2008) Genomic and proteomic approaches for targeting of an-giotensin-converting enzyme 2 for cardiovascular diseases. Curr. Opin. Cardiol. 23:364-9
6. Vickers C, et al. (2002) Hydrolysis of biological peptides by human angiotensin-converting en-zyme-related carboxypeptidase. J. Biol. Chem. 277:14838-43
7. Santos RAS, et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U S A. 100:8258-63
8. Santos RAS, Ferreira AJ, Simões e Silva AC. (2008) Recent advances in the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis. Exp. Physiol. 93:519-27
9. Hernández Prada JA, et al. (2008) Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihy-pertensive agents. Hypertension. 51:1312-7
10. Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA. (2006) Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J. Thromb. Haemost. 4:403-10
11. Li X, et al. (2008) Angiotensin converting en- zyme-2 is protective but downregulated in human and experimental lung fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 295:L178-85
12. Huentelman MJ, Zubcevic J, Katovich MJ, Raizada MK. (2004) Cloning and characterization of a secreted form of angiotensin-converting enzyme 2. Regul. Pept. 122:61-7
13. Sorg BS, Moeller BJ, Donovan O, Cao Y, Dewhirst MW. (2005) Hyperspectral imaging of hemoglo-bin saturation in tumor microvasculature and tumor hypoxia development. J. Biomed. Opt. 10:44004
14. Dedeugd C, Wankhede M, Sorg BS. (2009) Multi-modal optical imaging of microvessel network connective tissue. Appl. Opt. 48:D187-97
15. Crackower MA, et al. (2002). Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 417:822-8
16. Katovich MJ, Grobe JL, Huentelman M, Raizada MK. (2005) Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension. Exp. Physiol. 90:299-305
17. Dong B, et al. (2008) Overexpression of ACE2 enhances plaque stability in a rabbit model of ath-erosclerosis. Arterioscler. Thromb. Vasc. Biol. 28:1270-6
18. Ferreira AJ, et al. (2009) Evidence for angiotensin-converting enzyme 2 as therapeutic target for the prevention of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 179:1048-54
19. Nishimura H, et al. (1997) Angiotensin II in- creases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tis- sue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb. Haemost. 77:1189-95
20. van Leeuwen RT, et al. (1994) Angiotensin II in- creases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 90:362-8
21. Maczewski M, et al. (2008). Late ventricular re- modeling in nonreperfused acute myocardial in-farction in humans is predicted by angiotensin II type I receptor density on blood platelets. Int. J. Cardiol. 127:57-63
22. Jagroop IA, Mikhailidis DP. (2000) Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J. Hum. Hypertens. 14:581-5
23. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. (2002) Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 40:521-7
24. Kucharewicz I, et al. (2000) The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan. J. Renin Angiotensin Aldosterone Syst. 1:268-72
25. Kucharewicz I, Pawlak R, Matys T, Pawlak D, Buczko W. (2002) Antithrombotic effect of capto-pril and losartan is mediated by angiotensin-(1-7). Hypertension. 40:774-9
26. Fraga-Silva RA, et al. (2008) The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol. Med. 14:28-35
27. Pinheiro SV, et al. (2004) Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 44:490-6
28. Loscalzo J. (2001) Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 88:756-62.